Citations

Clear

152 citation(s) found for "Tobin, M D".

INNV-52. Mixed histiocytosis of the thoracic dura: a rare presentation of Mixed Erdheim-Chester Disease and Rosai-Dorfman Disease mimicking IgG4-Related Disease
Abeykoon, Jithma P. , Steel, Stephanie J., McKeon, Andrew, White, Jessica B. , Go, Ronald S. , Rech, Karen L. , Tobin, W. Oliver , McKeon, Andrew, Banks, Samantha A.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v237-v237

10.1093/neuonc/noaf201.0941 Get It

Abstract BACKGROUND Mixed histiocytic neoplasms with overlapping features of Erdheim-Chester Disease (ECD) and Rosai-Dorfman Disease (RDD) are extremely rare and diagnosis may be delayed due to lack of awareness and complex histology features. METHODS We report a case of mixed ECD/RDD misdiagnosed as IgG4-related disease and review the literature. RESULTS A 50-year-old man presented for evaluation of spastic paraparesis in the context of a thoracic dural lesion. Two years prior he developed an inflammatory monoarthritis concerning for rheumatoid arthritis unresponsive to methotrexate. Six months prior he developed leg spasms, gait spasticity, and urinary incontinence. MRI demonstrated a T2 hypointense enhancing epidural mass with spinal cord compression. Epidural biopsy showed fibrosis and non-specific inflammation. Given elevated serum IgG4 (170 mg/dL) and clinical findings, he was diagnosed with IgG4-related disease. He received high dose prednisone and etanercept without radiographic or clinical improvement. He then presented to our institution. Given high concern for RDD, he underwent FDG-PET CT which demonstrated an infiltrative process and FDG avid regions in the upper thoracic spinal cord, paranasal sinus, renal hilum, perivascular abdominal vessels, testicle, and multiple joint effusions. Biopsy of left testicle demonstrated CD163-positive histiocytes which coexpressed S100, cyclin D1, and OCT2, consistent with RDD. Biopsy of the left shoulder synovium demonstrated an atypical CD163-positive histiocytic infiltrate expressing Factor XIIIa, cyclin D1 and S100 (partial), and appeared negative for OCT2, consistent with ECD. The atypical histiocytes in both biopsies were negative for CD1a and BRAF V600E by immunohistochemistry. Genomic sequencing of the testicular tissue demonstrated a MAP2K1 (Q56P) alteration. He was treated with radiation therapy targeting the dural lesion with temporarily worsening symptoms improved with steroids and started on cobimetinib. DISCUSSION This case expands on the phenotypic description of mixed ECD/RDD. Histiocytic neoplasms should be considered in the differential diagnosis of dural based lesions.
Tremor and disability outcomes following deep brain stimulation for multiple sclerosis-associated tremor
Banks, Samantha A. , Permezel, Fiona E., Jackson, Lauren , Tobin, W. Oliver , Kantarci, Orhun H. , Keegan, B. Mark , Miller, Kai J. , Klassen, Bryan T. , Baker, Matthew R , Flanagan, E P , Tobin, W Oliver , Keegan, B Mark , Pittock, Sean J , Banks, Samantha , Baker, Matthew , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | October 27, 2025 | Volume: 31 | Issue: 13 | Pages: 1583-1590

10.1177/13524585251387935 | PMID 41143324 Get It

Background: Tremor in multiple sclerosis (MS) is often refractory to medications. Deep brain stimulation (DBS) may help, but possible side effects and disease exacerbation limit its use. Objectives: Evaluate outcomes of DBS for MS-associated tremor. Methods: Retrospective review of 18 patients with MS-associated tremor who underwent DBS, analyzing Expanded Disability Status Scale (EDSS) and Fahn–Tolosa–Marin (FTM) tremor scores. Results: Median age at surgery was 49.5 years (range, 28–75), with postoperative follow-up 2.5 years (range, 0–22). No relapses (0/18) or new lesions (0/8) occurred postoperatively. All had ventral intermediate nucleus leads; other targets were not used in programming. EDSS remained stable (median 6 to 6.25; p = 0.2). FTM scores improved (median 14.5 to 10, p = 0.008). Patients with EDSS 3.5–6 had variable outcomes ( p = 0.02). Conclusions: DBS is a potential treatment for severe MS tremor and did not provoke relapse. Targeting VIM alone may optimize tremor control and maintain magnetic resonance imaging (MRI) access.
Percutaneous Spinal Cord Stimulator Enables Novel Clonus Biomarker and Management in Persons With Spinal Cord Injury and Multiple Sclerosis: An Exploratory Study
Asp, Anders J., Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Mills, Candee J. , Thoreson, Andrew R. , Bendel, Markus A. , Zhao, Kristin D. , Grahn, Peter J. , Solinsky, Ryan J, Trentadue, Taylor P , Fernandez, K A , Asp, Anders J., Jahanian, Omid , Hagedorn, Jonathan M. , Solinsky, Ryan , Tobin, W. Oliver

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | September 24, 2025 | Volume: 31 | Issue: 2 | Pages: 114-124

10.46292/sci24-00070 | PMID 41019413 Get It

Background: Spasticity is common in spinal cord injury (SCI) and multiple sclerosis (MS), and it can manifest as repeated, rhythmic muscle contractions called clonus. The spontaneous nature of clonus can disrupt independent performance of activities of daily living and negatively impact overall health and quality of life. Objectives: To quantify biomarkers of clonus and explore management of clonus in individuals with SCI or progressive MS using epidural spinal cord stimulation (ES) or dorsal root stimulation (DRS). Methods: Four male participants were included in this case series study: 3 with SCI and 1 with MS. All participants underwent temporary percutaneous ES lead placement over the dorsolateral thoracolumbar region of the spinal cord. Participants with SCI were also implanted with DRS leads at the L4 dorsal root. Clonus was elicited mechanically at the ankle while recording electromyography of the soleus muscle synchronized to direct spinal cord field potential recordings from ES and DRS percutaneous leads. Results: Clonus was evident as a prominent band (5-8 Hz) in recordings from ES leads, DRS leads, soleus muscle, and accelerometry. In 4 participants, percutaneous spinal stimulation reduced median clonus duration and cycle count. Clonus was immediately suppressed upon activation of spinal cord stimulation, and the suppression persisted even when clonus was reinitiated after turning off the stimulation. Conclusion: The use of objective biomarkers, including spinal cord potentials, to quantify clonus in real time combined with the immediate and reversible effects of stimulation highlight the potential of neuromodulation as a therapeutic tool for managing clonus. These data demonstrate preliminary efficacy of ES and DRS for clonus monitoring and treatment in 4 participants.
Genomewide association study of a homogeneous multiple sclerosis cohort: Tumefactive demyelination
Zhao-Fleming, Hannah , Decker, Paul A. , Kosel, Matthew , Kollmeyer, Thomas , Clarkson, Benjamin D. , Jenkins, Robert B. , Tobin, W. Oliver , Eckel‐Passow, Jeanette E. , Kollmeyer, Thomas M. , Zhao-Fleming, Hannah H, Jenkins, Robert, Tobin, W Oliver , Eckel-Passow, Jeanette E , Decker, Paul A. , Drucker, Kristen , Lachance, Daniel Honore , Howe, Charles L.

Mayo Clinic

Multiple Sclerosis Journal | September 8, 2025 | Volume: 31 | Issue: 10 | Pages: 1167-1174

10.1177/13524585251371984 | PMID 40916898 Get It

Background: Tumefactive demyelination (TD) is a rare variant of multiple sclerosis (MS) characterized by tumor-like lesions that often require aggressive management. Genome-wide association studies (GWAS) identified variants associated with MS; similar analyses in TD are lacking. Objective: A GWAS was performed to identify variants associated with TD. Methods: The case–control study included 142 TD cases and 293 controls. TD patients were required to have a demyelinating event and magnetic resonance imaging (MRI) showing one or more lesions. Controls were patients without a neurologic or systemic inflammatory disease or cancer. Logistic regression was used to compare cases versus controls for each variant; age, sex, and principal components were included as covariates. A p -value threshold of 5 × 10 −8 was GWAS significant and 5 × 10 −6 nominally significant. A polygenic risk score (PRS) was compared across TD and controls. Results: Variants on chromosome 14 (rs117797734, p = 2.06 × 10 −11 , odds ratio (OR) = 13.14) and chromosome 6 (most significant rs6936540, p = 5.5 × 10 −7 , OR = 2.61) near DCBLD1 were significant. Seven non-MHC and two MHC variants associated with MS were associated with TD. The PRS was significantly higher in TD versus controls. Conclusion: We identified novel regions associated with TD, demonstrating the importance of performing GWAS in homogeneous subtypes of MS. Further validation and functional experiments are necessary.
Cardiovascular degeneration in Erdheim-Chester disease: prevalence, burden, and outcomes
Tawfiq, R., Spears, Grant M. , Young, Jason R., Mahowald, Madeline , Tobin, W. Oliver , Patgunarajah, Ubenthira, Ruan, Gordon , Yi, Dongni , Zanwar, Saurabh , Gruber, Lucinda , Ravindran, Aishwarya , Sartori‐Valinotti, Julio C. , Vassallo, Robert , Ryu, Jay H. , Davidge‐Pitts, Caroline , Dasari, Surendra , Abeykoon, Jithma P. , Tawfiq, Reema K , Mahowald, Madeline K , Ruan, Gordon J , Acosta-Medina, Aldo A , Ravindran, Aishwarya , Shah, Mithun V , Bennani, N Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Sartori-Valinotti, J C , Vassallo, Robert , Ryu, Jay H , Witzig, T.E. , Goyal, Guarav , Abeykoon, Jithma P , Tobin, W Oliver , Rech, Karen L. , Koster, Matthew J. , Acosta‐Medina, Aldo A. , Shah, Meera , Bennani, N. Nora , Moustafa, Muhamad Alhaj , Hilal, Talal , Witzig, Thomas E. , Go, Ronald S. , Goyal, Gaurav

Mayo Clinic

Blood Advances | August 28, 2025 | Volume: 9 | Issue: 23 | Pages: 5988-6000

10.1182/bloodadvances.2025016608 | PMID 40875593 Get It

Abstract Erdheim-Chester disease (ECD) is a rare systemic histiocytic neoplasm, with cardiac morbidities, including cardiovascular (CV) risk factors and cardiac conditions, playing a significant yet poorly understood role in the disease burden. This study evaluated the prevalence, characteristics, and prognosis of ECD in patients with (ECD-C) and without cardiac involvement (ECD-noC) and compared the burden of cardiac morbidities with matched controls. Patients diagnosed with ECD between 1990 and 2021 at a tertiary center were included, with cardiac involvement centrally assessed using radiographic studies. Cardiac morbidities were compared with a control group without ECD, matched for age, sex, body mass index, and smoking history. Among 104 patients with ECD, 39 (37%) had cardiac involvement. Patients with ECD-C had higher rates of hypertension (67% vs 46%), hyperlipidemia (67% vs 40%), heart failure (36% vs 8%), and pericardial effusion (28% vs 2%) than those with ECD-noC. Compared with the matched non-ECD cohort, patients with ECD had higher prevalence of coronary artery disease (20% vs 7%), heart failure (18% vs 4%), and antihypertensive drug use (55% vs 40%). Notably, patients with ECD-C had inferior progression-free survival (PFS) from frontline therapy compared with patients with ECD-noC (5-year PFS, 28.3% vs 70.5%). These findings highlight the burden of CV risk factors and cardiac conditions in ECD, even without a clinical diagnosis of ECD-C. Importantly, this cardiac morbidity burden is substantial for patients with ECD-C compared with ECD-noC. Our findings highlight the need for comprehensive cardiac risk assessment and management strategies to improve patient outcomes.
A Mixed-Method Case Study to Evaluate Adoption of Clinical Decision Support for Cancer Symptom Management
Ridgeway, Jennifer L. , Pachman, Deirdre R. , Chlan, Linda L, Tofthagen, Cindy , Tobin, Kyle A., Grzegorcyzk, Veronica, Rahman, Parvez, Ruddy, Kathryn J. , Minteer, Sarah A. , Tofthagen, Cindy S , Ridgeway, Jennifer L , Rutten, Lila J. Finney , Griffin, Joan M. , Austin, Jessica D. , Chlan, Linda L. , Tobin, Kyle A., Cheville, Andrea

Mayo Clinic

Applied Clinical Informatics | August 22, 2025 | Volume: 16 | Issue: 04 | Pages: 804-814

10.1055/a-2587-6081 | PMID 40846308 Get It

AbstractElectronic patient-reported outcome measures (ePROMs) can improve care for people with cancer, but effectiveness hinges on well-supported integration in clinical settings.We evaluated clinician use of specific clinical decision support (CDS) tools in the electronic health record (EHR) designed to facilitate timely, clinically appropriate responses to ePROM scores for six symptoms commonly experienced by cancer patients.The parent pragmatic trial, which took place at Mayo Clinic (Rochester, Minnesota, United States) and its affiliated community health care system between March 2019 and January 2023, evaluated the population-level effectiveness and implementation of an ePROM surveillance and EHR-facilitated collaborative care symptom management intervention. The present evaluation used a case study approach with four data sources: (1) clinician interactions with CDS tools abstracted from the EHR; (2) clinician notes identified with an institution-specific textual search tool; (3) qualitative interviews and group discussions with care teams; and (4) administrative records reviewed to identify training and outreach to care teams.EHR metrics showed very low adoption of CDS tools including alerts and symptom-specific order sets, despite educational outreach and information technology support provided to clinical care teams. Qualitative findings revealed that CDS use was not easy to integrate into busy clinical workflows and highlighted clinician perceptions that the collaborative care intervention provided additional patient support that reduced clinicians' need to utilize CDS tools. They also highlight the importance of contextual factors, including institutional priorities and EHR changes.This pragmatic clinical trial case study found limited adoption of EHR CDS tools that had been developed to increase clinicians' awareness of and responses to ePROM data. Findings suggest the need to align clinician and organizational implementation strategies, simplify CDS tools to fit practice expectations, and identify and address contextual factors that could undercut strategies like education and peer support. This may be especially important for teams who aim to iteratively evaluate and refine CDS and implementation strategies for multicomponent interventions or introduce new strategies that are responsive to barriers while maintaining scalability.
Percutaneous epidural spinal cord stimulation immediately reduces clonus in an individual with multiple sclerosis
Anders, Jennifer , Jahanian, Omid , Gill, Megan L., Veith, Daniel D. , Fernandez, K. A. , Mills, Candee J. , Thoreson, Andrew R. , Larson, C. W., Sagen, Jessica, Grahn, Peter J. , Zhao, Kristin D. , Asp, Anders J , Fernandez, K A , Larson, Carol M, Sagen, Jessica A., Tobin, W Oliver , Trentadue, Taylor P , Jahanian, Omid , Larson, Carol M, Tobin, W. Oliver

Mayo Clinic

Multiple Sclerosis Journal | July 28, 2025 | Volume: 32 | Issue: 1 | Pages: 144-147

10.1177/13524585251357143 | PMID 40719678 Get It

Clonus is a disabling symptom of upper motor neuron dysfunction in patients with multiple sclerosis (MS). We report immediate termination of mechanically evoked clonus by epidural lumbosacral spinal cord stimulation (ES) in a 58-year-old man with secondary progressive MS. This observation was captured during training using video and skin surface electromyography of soleus muscle activity. ES immediately reduced mechanically evoked clonus duration and cycle count compared to trials without stimulation, as determined by a Kruskal–Wallis test ( p < 0.05, n = 2–3 trials), and reverted to baseline status when stimulation was off.
Redefining risk stratification in pLCH
Abeykoon, Jithma P. , Tobin, W. Oliver , Tobin, W Oliver

Mayo Clinic

Blood | July 10, 2025 | Volume: 146 | Issue: 2 | Pages: 136-138

10.1182/blood.2025029134 | PMID 40638205 Get It

Dissecting the biology of gliomagenesis: Evaluating the interaction between IDH tumor mutation and germline variants
Kosel, Matthew , Decker, Paul A. , Kollmeyer, Thomas M. , Shurtz, Anne K., Molinaro, Annette M. , Moassefi, Mana , Wrensch, Margaret , Jenkins, Robert B. , Eckel‐Passow, Jeanette E. , Vaubel, Rachel A, Jenkins, RB , Eckel-Passow, Jeanette E , Kollmeyer, Thomas , Decker, Paul A. , Drucker, Kristen , Molinaro, Annette M. , Conte, Gian Marco , Moassefi, Mana , Erickson, Bradley J. , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Vaubel, Rachael A. , Lachance, Daniel Honore , Tobin, W. Oliver

Mayo Clinic

Neuro-Oncology Advances | July 8, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdaf147 | PMID 40709013 Get It

Abstract Background The CCDC26 germline variant rs55705857 is causal for development of IDH mutant (IDHmut) adult glioma. However, ~60% of IDHmut patients do not carry the rs55705857 risk allele. We aimed to identify variants associated with developing IDHmut glioma among patients that do not have the rs55705857 risk allele and to further understand development of IDHwt glioma. Methods We used three datasets that included 1216 IDHmut and 1442 IDHwt glioma patients and a case–case design to perform genome-wide association (GWAS) analyses comparing IDHmut versus IDHwt glioma. Analyses were performed overall and stratified by rs55705857 genotype and sex. Multivariable logistic regression and regression trees were used to develop models to predict IDH status using germline variants, age, and contrast enhancement on MRI. Results Three regions were identified comparing IDHmut versus IDHwt: rs55705857 (meta P-value [P] = 1.35 × 10−43), PHLDB1 (rs7125115, P = 3.46 × 10−17), and D2HGDH (rs71430382, P = 2.43 × 10−12). When analyzing only patients that do not have the rs55705857 risk allele, PHLDB1 (rs7125115, P = 1.73 × 10−13) and D2HGDH (rs71430382, P = 8.86 × 10−10) were identified. Among patients who have the rs55705857 risk allele, four variants between ROBO1 and ROBO2 (rs4680975, P = 4.65 × 10−7) increased the likelihood of having an IDHwt tumor. Tumor expression of ROBO1 was associated with rs4680975 genotype in IDHwt patients that have the rs55705857 risk allele (P = 0.034). Multivariable logistic analysis demonstrated that rs55705857, rs71430382 (D2HGDH), and age predicted IDH mutation status. Conclusions To understand the development of adult glioma, we demonstrate that D2HGDH and PHLDB1 should be prioritized for functional studies in IDHmut tumors. The ROBO1 region warrants further investigation in IDHwt tumors.